Table 3.
Respiratory and haematological dysfunction, ICU monitoring and treatment
|
No cancer (n = 2674) |
Solid tumours (n = 404) |
Haematological cancer (n = 69) |
|
| Mechanical ventilation | 1724 (64.5%) | 253 (62.6%) | 48 (69.6%) |
| ALI/ARDS | 325 (12.2%) | 47 (11.6%) | 21 (30.4%)$ |
| PaO2/FiO2 | 202.8 (133.4 to 295.0) | 224.0 (144.0 to 324.3) | 140.0 (94.0 to 206.2)$ |
| MV, days/patient | 3.0 (1.0 to 7.0) | 2.0 (1.0 to 6.0) | 4.0 (2.0 to 6.0) |
| Leucopenia | 43 (1.6%) | 14 (3.5%)* | 17 (24.6%)$ |
| Thrombocytopenia | 373 (13.9%) | 52 (12.9%) | 35 (50.7%)$ |
| Pulmonary artery catheter | 430 (16.1%) | 37 (9.2%)$ | 14 (20.3%) |
| Central venous catheter | 1896 (70.9%) | 317 (78.5%) | 59 (85.5%) |
| Arterial catheter | 1882 (70.4%) | 304 (75.2%) | 54 (78.3%)$ |
| Vasopressors | 1089 (40.7%) | 163 (40.3%) | 41 (59.4%)* |
| Inotropes | 505 (18.9%) | 61 (15.1%) | 20 (29.0%)* |
| Haemofiltration | 184 (6.9%) | 16 (4.0%) | 11 (15.9%)* |
| Haemodialysis | 121 (4.5%) | 16 (4.0%) | 4 (5.8%) |
ALI: acute lung injury; ARDS: acute respiratory distress syndrome; FiO2: inspired fraction of oxygen; ICU = intensive care unit; MV: mechanical ventilation; PaO2: arterial partial pressure of oxygen.
* p < 0.05 versus no-cancer group; $ p < 0.001 versus no-cancer group.
Data are presented as number (percentage) or median (interquartile range)